Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party

Bone Marrow Transplantation volume 54, pages 1625–1631 (2019)Cite this article

Subjects

Abstract

The present study aimed at describing the outcome of patients with HIV-associated lymphomas following autologous hematopoietic stem cell transplantation (autoHCT) in the rituximab and combined antiretroviral therapy (cART) era. Eligible for this retrospective study were HIV-positive patients with lymphoma who received autoHCT between 2007 and 2013. A total of 118 patients were included with a median age of 45 years (range 24–66). Underlying diagnoses were diffuse large B cell lymphoma in 47%, Hodgkin lymphoma in 24%, Burkitt lymphoma in 18%, and plasmablastic lymphoma in 7% of patients. Disease status at autoHCT was complete remission in 44%, partial remission (PR) in 38%, and less than PR in 18% of the patients. With a median follow-up of 4 years, 3-year non-relapse mortality, incidence of relapse, progression-free survival (PFS) and overall survival (OS) were 10%, 27%, 63% and 66%, respectively. By multivariate analysis, disease status less than PR but not CD4+ cell count at the time of autoHCT was a significant predictor of unfavorable PFS and OS. In conclusion, in the era of cART and chemoimmunotherapy, the outcome of autoHCT for HIV-related lymphoma is driven by lymphoma-dependent risk factors rather than by characteristics of the HIV infection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62.

    Article  Google Scholar 

  2. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28(8):1181–91.

  3. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27:884–90.

    Article  Google Scholar 

  4. Goedert JJ, Bower M. Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection. Curr Opin Oncol. 2012;24:531–6.

    Article  CAS  Google Scholar 

  5. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786–91.

    Article  CAS  Google Scholar 

  6. Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30:4111–6.

    Article  Google Scholar 

  7. Ribera JM, Garcia O, Grande C, Esteve J, Oriol A, Bergua J, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119:1660–8.

    Article  CAS  Google Scholar 

  8. Coutinho R, Pria AD, Gandhi S, Bailey K, Fields P, Cwynarski K, et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS. 2014;28:689–97.

    Article  CAS  Google Scholar 

  9. Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103:857–64.

    Article  CAS  Google Scholar 

  10. Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, et al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol. 2015;168:806–10.

    Article  Google Scholar 

  11. Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016;128:1050–8.

    Article  CAS  Google Scholar 

  12. Balsalobre P, Diez-Martin JL, Re A, Michieli M, Ribera JM, Canals C, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27:2192–8.

    Article  Google Scholar 

  13. Diez-Martin JL, Balsalobre P, Re A, Michieli M, Ribera JM, Canals C, et al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113:6011–4.

    Article  CAS  Google Scholar 

  14. Ramaswami R, Pria AD, Parker K, McCann S, Kanfer EJ, Nelson M, et al. Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma. Bone Marrow Transplant. 2016;51:1609–11.

    Article  CAS  Google Scholar 

  15. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–25.

    Article  Google Scholar 

  16. Eichenauer DA, Engert A, Andre M, Federico M, Illidge T, Hutchings M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii70–5.

    Article  Google Scholar 

  17. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037–56.

    Article  CAS  Google Scholar 

  18. Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet. 2000;355:1071–2.

    Article  CAS  Google Scholar 

  19. Krishnan A, Molina A, Zaia J, Smith D, Vasquez D, Kogut N, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105:874–8.

    Article  CAS  Google Scholar 

  20. Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant. 2012;18:788–93.

    Article  Google Scholar 

  21. Robinson SP, Boumendil A, Finel H, Blaise D, Poire X, Nicolas-Virelizier E, et al. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2016;51:365–71.

    Article  CAS  Google Scholar 

  22. Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1729–36.

    Article  CAS  Google Scholar 

  23. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a multicenter phase II study. Annals Oncol. 2005;16:1359–65.

    Article  CAS  Google Scholar 

  24. Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant. 2016;51:212–8.

    Article  CAS  Google Scholar 

  25. Cattaneo C, Finel H, McQuaker G, Vandenberghe E, Rossi G, Dreger P. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience. Biol Blood Marrow Transplant. 2015;21:1146–7.

    Article  Google Scholar 

  26. Re A, Gini G, Rupolo M, Levis A, Bandera A, Liberati AM, et al. Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. Bone Marrow Transplant. 2018;53:228–30.

    Article  CAS  Google Scholar 

  27. Welz T, Wyen C, Hensel M. Drug interactions in the treatment of malignancy in HIV-infected patients. Oncol Res Treat. 2017;40:120–7.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The study was supported by the EBMT Lymphoma Working Party. The study was supported by the EBMT Lymphoma Working Party.

Author information

Authors and Affiliations

  1. University Hospital of Cologne, Cologne, Germany

    Kai Hübel

  2. Hematology, Spedali Civili di Brescia, Brescia, Italy

    Alessandro Re & Chiara Cattaneo

  3. EBMT Paris Study Office/CEREST-TC, Paris, France

    Ariane Boumendil

  4. Hopital Saint-Antoine, EBMT Paris Study Office, Paris, France

    Herve Finel

  5. Rotkreuzklinikum München, München, Germany

    Marcus Hentrich

  6. University Hospital’s Bristol NHS Foundation Trust, Bristol, UK

    Stephen Robinson

  7. Praxis am Ebertplatz, Cologne, Germany

    Christoph Wyen

  8. Centro di Riferimento Oncologico, Aviano, Italy

    Mariagrazia Michieli

  9. Hammersmith Hospital London, London, UK

    Edward Kanfer

  10. Hospital General Universitario Gregorio Maranon, Madrid, Spain

    Jose Luis Diez-Martin & Pascual Balsalobre

  11. Hospital Center University, Montpellier, France

    Laure Vincent

  12. University Hospital Antwerpen, Antwerpen, Belgium

    Wilfried Schroyens

  13. Hospital Universitaria Germans Trias i Pujol, Barcelona, Spain

    Josep Maria Ribera Santasusana

  14. University Hospital Eppendorf, Hamburg, Germany

    Nicolaus Kröger

  15. Klinikum Harlaching, München, Germany

    Xaver Schiel

  16. University College Hospital, London, UK

    Kate Cwynarski

  17. Hospital de la Santa Creu i Santpau, Barcelona, Spain

    Albert Esquirol

  18. Hospital dos Capuchos, Lisboa, Portugal

    Aida Botelho Sousa

  19. St. Bartholomew’s Hospital, Barts Health NHS Trust, London, UK

    Silvia Montoto

  20. University Hospital of Heidelberg, Heidelberg, Germany

    Peter Dreger

Authors
  1. Kai Hübel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Re
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ariane Boumendil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Herve Finel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marcus Hentrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stephen Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christoph Wyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mariagrazia Michieli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Edward Kanfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jose Luis Diez-Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Pascual Balsalobre
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Laure Vincent
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Wilfried Schroyens
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Josep Maria Ribera Santasusana
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Nicolaus Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Xaver Schiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Kate Cwynarski
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Albert Esquirol
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Aida Botelho Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Chiara Cattaneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Silvia Montoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Peter Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kai Hübel.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hübel, K., Re, A., Boumendil, A. et al. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. Bone Marrow Transplant 54, 1625–1631 (2019). https://doi.org/10.1038/s41409-019-0480-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0480-x

This article is cited by

Search

Advanced search

Quick links